Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.76 USD | +0.33% | -0.96% | +20.31% |
16/04 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
11/04 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.31% | 702M | |
+3.25% | 106B | |
+7.02% | 23.47B | |
-14.80% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.41% | 16.78B | |
+5.32% | 14.41B | |
+37.05% | 12.86B | |
+328.53% | 8.78B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20